Clinical trials: Fat; Liver
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
Obesity and type 2 Diabetes Mellitus prevalence has doubled in the last 30 years and nearly one fifth of UAE population has Type 2 Diabetes while more than quarter has obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Type 2 Diabetes, Liver Fat
- Trial name
- NCT05751720
- Testing
- GIP/GLP-1a
- Where
- United Arab Emirates
- Volunteers
- 30 people
- Sponsor
- Dr Adnan Agha
Non-Alcoholic Fatty Liver Disease, Type2 Diabetes
Characteristics of NAFLD Among Type 2 Diabetes Patients
Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found.
- Trial name
- NCT04999124
- Testing
- Screening and studying characteristics
- Where
- Belgium
- Volunteers
- 1,762 people
- Sponsor
- Ziekenhuis Oost-Limburg
Non-Alcoholic Fatty Liver Disease
Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production
All subjects will be evaluated by the Research Nurse at the Clinical Translational Research Center (CTRC) Outpatient Clinic to obtain informed consent, a brief medical history, weight, body mass index, waist/hip circumference and…
- Trial name
- NCT01262326
- Testing
- Calorie and Carbohydrate Restriction
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Liver Fat, Cardiac Function
Short-term Fat Overfeeding on the Effects of Liver Metabolism
Despite work showing the overconsumption of saturated fatty acids (SFA) to be metabolically deleterious, debate continues about whether there is a link between SFA and cardiovascular disease risk.
- Conditions
- Liver Fat, Cardiac Function, Lipid Disorder, Adiposity
- Trial name
- FOS (NCT05962190)
- Testing
- Diet
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Aging, Inspiratory Muscle Weakness
Effect of Inspiratory Muscle Training on Diaphragm Muscle Thickness, Fatty Liver Density and Aerobic Capacity in Elderly Men: A Randomized Controlled Trial
This randomized controlled trial aims to investigate the effects of a 4-week inspiratory muscle training (IMT) program on diaphragm muscle thickness, fatty liver density, functional capacity, and quality of life in elderly men…
- Conditions
- Aging, Inspiratory Muscle Weakness, Fatty Liver, Reduced Functional Capacity
- Trial name
- IMT AND ELDERL (NCT07193082)
- Testing
- Experimental Inspiratory Muscle Training (IMT Group), Control Group: No inspiratory muscle training.
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gümüşhane Universıty
HIV Infections, Fatty Liver
Liver Steatosis and Stiffness in HIV
Background: With the advances in treatment and clinical care, individuals with human immunodeficiency virus (HIV) infection have experienced an increase in life expectancy.
- Conditions
- HIV Infections, Fatty Liver, Liver Fibroses
- Trial name
- NCT03599882
- Testing
- Fibroscan
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Chang Gung Memorial Hospital
Non-Alcoholic Fatty Liver Disease
Ultrasound Liver Fat Quantification on Pediatric Patients
This prospective study aims to recruit pediatric patients with confirmed or suspected non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatosis hepatitis (NASH) and who are eligible for standard ultrasound and MRI…
- Trial name
- NCT06095479
- Testing
- 2D ultrasound scan and MRI examination
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Philips (China) Investment CO., LTD
NAFLD - Nonalcoholic Fatty Liver Disease, NASH - Nonalcoholic Steatohepatitis
Effects of Exercise on VLDL-TG Metabolism
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH) and cirrhosis.
- Trial name
- NCT03678727
- Where
- Denmark
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Type 2 Diabetes (T2D)
Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 with Non-alcoholic Hepatic Steatosis
The prevalence of fatty liver disease (NAFLD: Non-Alcoholic Fatty Liver Disease or to a more severe degree NASH: Non-Alcoholic SteatoHepatitis) reached 40-70% in subjects with type 2 diabetes (T2D).
- Trial name
- STEATO-POMPE (NCT04270656)
- Testing
- Insulin pump therapy, Multi-injection treatment ( MDI ).
- Where
- 9 sites in France
- Volunteers
- 46 people
- Sponsor
- Nantes University Hospital
Non-Alcoholic Fatty Liver Disease
Quality of Life in Non-alcoholic Fatty Liver Disease (QOLNAFLD)
Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent disorder which is directly linked to lifestyle patterns and is associated with poor quality of life, increased fatigue and psychological distress.
- Trial name
- QOLNAFLD (NCT03613480)
- Testing
- Motivational Interviewing
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University Hospital of Patras
Obesity, Dyslipidemia
Reduction of Sweetened Beverages and Intrahepatic Fat
The study will enroll 68 overweight male and female subjects with a high (> 2 3dl-can soda/day) consumption of sweetened beverage per day.
- Conditions
- Obesity, Dyslipidemia, Metabolic Syndrome
- Trial name
- REDUCS (NCT01394380)
- Testing
- artificially sweetened sodas
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- University of Lausanne
Healthy, NAFLD
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
The primary objective of this study is to evaluate the effect of itraconazole, a strong inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A, CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of…
- Trial name
- NCT04845646
- Testing
- ASC41, Itraconazole, Phenytoin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
Acute Pancreatitis, Nonalcoholic Fatty Liver Disease
Association Between Nonalcoholic Fatty Liver Disease and Acute Pancreatitis
The early evaluation of AP severity are vital. Previous studies have shown non-alcoholic fatty liver disease (NAFLD) is associated with severity of acute pancreatitis (AP).
- Trial name
- NCT03566173
- Where
- China
- Volunteers
- 1,662 people
- Sponsor
- Ningbo No. 1 Hospital
Fatty Liver Disease, Fatty Liver
Impact of Time-restricted Feeding in NAFLD
This is a randomised controlled study of patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Patients will be trained according to the 10 rules of a healthy nutrition according to the German Association for Nutrition (DGE).
- Conditions
- Fatty Liver Disease, Fatty Liver, Fatty Liver, Nonalcoholic
- Trial name
- NAFLD-TRF (NCT05220956)
- Testing
- Intermittent fasting, DGE diet
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johannes Gutenberg University Mainz
Fatty Liver Disease
Assessment of FibbroScan in Diagnosing MASLD Among the Chinese Population With Obesity
The non-invasive evaluation of liver steatosis and fibrosis with FibroScan is a routinely procedure in clinical practice for people with obesity.
- Trial name
- MASLD (NCT06720766)
- Testing
- FibbroScan and biopsy
- Where
- China
- Volunteers
- 565 people
- Sponsor
- The Third People's Hospital of Chengdu
Liver Cirrhosis, Fatty Liver
Multiparametric MR for Rapid Imaging Assessment of the Liver
The RIAL study aims to investigate whether non-invasive measurement of liver fat, iron content and fibrosis are as accurate as liver biopsy specimens in determining if patients have non-alcoholic fatty liver disease (NAFLD) or…
- Trial name
- RIAL (NCT01543646)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Oxford
Nonalcoholic Steatohepatitis (NASH)
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension.
- Trial name
- NCT04880031
- Testing
- Efimosfermin
- Where
- 48 sites in United States
- Volunteers
- 231 people
- Sponsor
- GlaxoSmithKline
NAFLD, NASH
THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis
- Trial name
- FRAMES (NCT04925362)
- Testing
- Biological specimens, Additional visit
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nonalcoholic Fatty Liver Disease, HIV
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
A subset of patients with NAFLD that have not been extensively studied are those infected with human immunodeficiency virus (HIV). Currently, there is no FDA approved treatment for NAFLD or NASH.
- Trial name
- ARRIVE (NCT02684591)
- Testing
- Aramchol
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Non-Alcoholic Fatty Liver Disease, Obesity
Influence of the Diversity and Composition of the Microbiota in the Development of Pediatric Fatty Liver
The objectives of the present study are: 1) to identify the intestinal and salivary microbiota associated with the presence and severity of hepatic steatosis in children (Study I: case-control study), and 2) to develop a…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- MicroKid (NCT04575506)
- Testing
- Multidisciplinary intervention program
- Where
- 2 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Pública de Navarra
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.